| HbA1c reduction from baseline (%) | HbA1c relative reduction from baseline (%) | Change in related prevalence of complications |
Treatments |
|
|
|
1.2 mg Lirag + Glim + Met | −1.3% | −16.67% | −66.67% |
1.8 mg Lirag + Glim + Met | −1.4% | −17.95% | −71.79% |
Glim 4 g + Met | −1.3% | −16.67% | −66.67% |